GENENTECH, INC for GENENTECH INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
TAX - general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations.; Tax reform, general corporate and international taxation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant Director |
Copyright/Patent/Trademark CPT
Cyber Security, transpacific partnership; Intellectual Property and Process Patent Issues - (all provisions)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| ELI KOGAN | Assistant Director |
Health Issues HCR
S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals; Medical Countermeasure Stockpile 340B Drug Discounting Program; FOR - Issues related to the treatment of biologics in international health programs specifically under the Pan American Health Organization
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNA GRIFFIN | Sr. Director |
| EVAN MORRIS | Vice President Government affairs |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligiable demonstratins and relaed provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Act of 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicare Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNA GRIFFIN | Sr. Director |
| EVAN MORRIS | Vice President Government affairs |
Budget/Appropriations BUD
BUD: Following issues related to the budget and appropriations process FY 14 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation.; TAX - general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations. Issues related to FDA & HHS program funding, FY15 Labor Health and Human Services, and Education, and Related Agencies, H.R. 4800, and FY 15 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| ANNA GRIFFIN | Sr. Director |
| ELI KOGAN | Assistant director |
Pharmacy PHA
PHA - Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare presciption drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation; 340(b) Drug Discount Program;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assistant Director |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.